Boostrix™

BIOLOGICAL7 trials

Sponsors

GlaxoSmithKline, DBV Technologies

Conditions

Acellular PertussisDiphtheriaDiphtheria-Tetanus-acellular Pertussis VaccinesTetanusWhooping Cough

Phase 1

Viaskin Pertussis Vaccine Trial

CompletedNCT03035370

DBV TechnologiesWhooping Cough

Start: 2016-09-05End: 2018-04-25Updated: 2020-03-02

Phase 3

Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years

CompletedNCT00346073

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Tetanus

Start: 2006-07-13End: 2007-03-07Updated: 2018-08-07

Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®

CompletedNCT01277705

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Tetanus

Start: 2002-01-31End: 2002-04-30Updated: 2016-09-07

Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children

CompletedNCT01988857

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Tetanus

Start: 2014-02-22End: 2014-05-10Updated: 2018-08-02

Phase 4

Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058

CompletedNCT00548171

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Diphtheria-Tetanus-acellular Pertussis Vaccines +1

Start: 2007-11-05End: 2008-04-30Updated: 2020-01-13

Evaluation of Boostrix™10 Years After Previous Booster Vaccination

CompletedNCT01147900

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Tetanus

Start: 2010-06-15End: 2012-05-08Updated: 2018-08-20

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women

CompletedNCT02377349

GlaxoSmithKlineDiphtheria-Tetanus-acellular Pertussis Vaccines

Start: 2015-10-14End: 2017-10-24Updated: 2020-01-28

Related Papers

Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial

Vaccine2021-02-2112 citations

Safety and immunogenicity of the epicutaneous reactivation of pertussis toxin immunity in healthy adults: a phase I, randomized, double-blind, placebo-controlled trial.

2020-09-0510 citations

Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial.

2019-11-2428 citations

Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.

2015-04-144 citations

Decennial administration in young adults of a reduced-antigen content diphtheria, tetanus, acellular pertussis vaccine containing two different concentrations of aluminium

Vaccine2015-01-198 citations

A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix™) is immunogenic and well tolerated in adults.

2010-10-2341 citations